53,124 Shares in Grail, Inc. (NASDAQ:GRAL) Bought by Eagle Health Investments LP

Eagle Health Investments LP purchased a new stake in Grail, Inc. (NASDAQ:GRAL) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 53,124 shares of the company’s stock, valued at approximately $948,000. Grail comprises approximately 0.2% of Eagle Health Investments LP’s investment portfolio, making the stock its 18th biggest position.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. FNY Investment Advisers LLC purchased a new stake in shares of Grail in the fourth quarter worth about $26,000. Lindbrook Capital LLC purchased a new position in Grail during the fourth quarter valued at approximately $28,000. Wellington Shields Capital Management LLC acquired a new position in Grail in the fourth quarter valued at approximately $33,000. New York State Common Retirement Fund purchased a new stake in Grail in the 4th quarter worth approximately $59,000. Finally, Wilmington Savings Fund Society FSB acquired a new stake in shares of Grail during the 4th quarter worth approximately $64,000.

Insider Activity at Grail

In other Grail news, CEO Robert P. Ragusa sold 7,625 shares of the stock in a transaction on Friday, March 7th. The shares were sold at an average price of $31.21, for a total transaction of $237,976.25. Following the transaction, the chief executive officer now directly owns 828,662 shares of the company’s stock, valued at $25,862,541.02. This trade represents a 0.91 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Aaron Freidin sold 1,816 shares of the business’s stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $31.20, for a total transaction of $56,659.20. Following the sale, the chief financial officer now directly owns 335,170 shares of the company’s stock, valued at $10,457,304. This represents a 0.54 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 11,550 shares of company stock valued at $360,436.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley boosted their target price on shares of Grail from $16.00 to $20.00 and gave the company an “equal weight” rating in a research note on Tuesday, March 18th.

Grail Stock Performance

NASDAQ:GRAL opened at $28.39 on Thursday. Grail, Inc. has a 52 week low of $12.33 and a 52 week high of $63.99. The stock’s 50-day moving average price is $33.62 and its 200-day moving average price is $22.21.

Grail (NASDAQ:GRAL) last issued its quarterly earnings data on Thursday, February 20th. The company reported ($1.86) EPS for the quarter, beating the consensus estimate of ($4.41) by $2.55. The business had revenue of $38.25 million during the quarter, compared to analyst estimates of $35.33 million. As a group, equities research analysts anticipate that Grail, Inc. will post -15.15 EPS for the current fiscal year.

About Grail

GRAIL, Inc is a healthcare company. It engages in the development of a technology for early detection of cancer. The company was founded by Jeffrey T. Huber, William H. Rastetter, and Mostafa Ronaghi on September 11, 2015 and is headquartered in Menlo Park, CA.